;Crohn's disease: Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of<unk>  versus placebo in moderate to severe active Crohn's disease. ;Axial spondyloarthritis: In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis. ;Rheumatoid arthritis:<unk>  appears beneficial in those with rheumatoid arthritis.
Certolizumab pegol
Mepolizumab
Vedolizumab
Belatacept
Natalizumab
Satralizumab
Emicizumab
Nemolizumab